NRSN NeuroSense Therapeutics Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1875091 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-9.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-2,175.0%
ROA-397.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets251.8%
Debt / equity—
Current ratio0.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-123.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $6.23M | $5.70M | $7.27M | $5.59M | — |
| SG&A expense | $4.86M | $4.20M | $4.78M | $4.97M | $2.50M |
| Operating income | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -$5.59M |
| Interest expense | — | — | $2.21M | $45,000 | $1.19M |
| Net income | -$11.12M | -$10.21M | -$10.11M | -$10.49M | -$4.04M |
| EBITDA | -$11.07M | -$9.88M | -$12.03M | -$10.54M | — |
| EPS (basic) | -0.44 | -0.54 | -0.74 | -0.91 | -0.65 |
| EPS (diluted) | -0.44 | -0.54 | -0.74 | -0.91 | -0.65 |
| Weighted avg. shares (diluted) | 25.48M | 18.60M | 13.64M | 11.50M | — |
| Balance sheet | |||||
| Cash & equivalents | $166,000 | $3.38M | $2.64M | $3.54M | $11.06M |
| Short-term investments | — | — | — | $3.55M | — |
| Current assets | $778,000 | $4.40M | $2.92M | $7.38M | $11.41M |
| PP&E, net | $58,000 | $66,000 | $85,000 | $77,000 | $19,000 |
| Total assets | $1.03M | $4.58M | $3.19M | $7.72M | $11.43M |
| Current liabilities | $2.52M | $1.99M | $3.46M | $1.73M | $597,000 |
| Total liabilities | $2.59M | $1.99M | $4.94M | $1.87M | $2.42M |
| Shareholders' equity | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M |
| Shares outstanding | 32.56M | 23.23M | 15.38M | 11.78M | 2.00M |
| Cash flow statement | |||||
| Operating cash flow | -$7.67M | -$10.13M | -$8.35M | -$7.62M | -$1.54M |
| Capital expenditure | $8,000 | $3,000 | $29,000 | $70,000 | $17,000 |
| Free cash flow | -$7.68M | -$10.14M | -$8.38M | -$7.69M | -$1.56M |
| Investing cash flow | -$8,000 | $1,000 | $3.47M | -$3.59M | -$17,000 |
| Financing cash flow | $4.43M | $10.91M | $3.98M | $3.77M | $11.90M |
| Depreciation & amortization | $16,000 | $22,000 | $21,000 | $12,000 | — |
| Stock-based compensation | $2.14M | $557,000 | $1.54M | $1.73M | $4.16M |
| Dividends paid | — | — | $310,000 | $310,000 | $29,000 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.